These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17392236)

  • 1. Pioglitazone vs glimepiride and carotid intima-media thickness.
    Giugliano D; Esposito K
    JAMA; 2007 Mar; 297(12):1315-6; author reply 1316-7. PubMed ID: 17392236
    [No Abstract]   [Full Text] [Related]  

  • 2. Pioglitazone vs glimepiride and carotid intima-media thickness.
    Kida Y; Sato T
    JAMA; 2007 Mar; 297(12):1316; author reply 1316-7. PubMed ID: 17392237
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
    Mazzone T; Meyer PM; Feinstein SB; Davidson MH; Kondos GT; D'Agostino RB; Perez A; Provost JC; Haffner SM
    JAMA; 2006 Dec; 296(21):2572-81. PubMed ID: 17101640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.
    Davidson M; Meyer PM; Haffner S; Feinstein S; D'Agostino R; Kondos GT; Perez A; Chen Z; Mazzone T
    Circulation; 2008 Apr; 117(16):2123-30. PubMed ID: 18413496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.
    Polonsky T; Mazzone T; Davidson M
    Trends Cardiovasc Med; 2009 Apr; 19(3):94-9. PubMed ID: 19679266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study.
    Davidson MH; Beam CA; Haffner S; Perez A; D'Agostino R; Mazzone T
    Arterioscler Thromb Vasc Biol; 2010 Sep; 30(9):1873-6. PubMed ID: 20576945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
    Mizoguchi M; Tahara N; Tahara A; Nitta Y; Kodama N; Oba T; Mawatari K; Yasukawa H; Kaida H; Ishibashi M; Hayabuchi N; Harada H; Ikeda H; Yamagishi S; Imaizumi T
    JACC Cardiovasc Imaging; 2011 Oct; 4(10):1110-8. PubMed ID: 21999871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes.
    Forst T; Hohberg C; Fuellert SD; Lübben G; Konrad T; Löbig M; Weber MM; Sachara C; Gottschall V; Pfützner A
    Horm Metab Res; 2005 Aug; 37(8):521-7. PubMed ID: 16138267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects.
    Joya-Galeana J; Fernandez M; Cervera A; Reyna S; Ghosh S; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
    Diabetes Metab Res Rev; 2011 May; 27(4):373-82. PubMed ID: 21309063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone vs glimepiride in the PERISCOPE trial.
    Fresco C
    JAMA; 2008 Aug; 300(7):787; author reply 788. PubMed ID: 18714055
    [No Abstract]   [Full Text] [Related]  

  • 12. Pioglitazone vs glimepiride in the PERISCOPE trial.
    Shah R
    JAMA; 2008 Aug; 300(7):787-8; author reply 788. PubMed ID: 18714054
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
    Nissen SE; Nicholls SJ; Wolski K; Nesto R; Kupfer S; Perez A; Jure H; De Larochellière R; Staniloae CS; Mavromatis K; Saw J; Hu B; Lincoff AM; Tuzcu EM;
    JAMA; 2008 Apr; 299(13):1561-73. PubMed ID: 18378631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients.
    Nakamura T; Matsuda T; Kawagoe Y; Ogawa H; Takahashi Y; Sekizuka K; Koide H
    Metabolism; 2004 Oct; 53(10):1382-6. PubMed ID: 15375799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PERISCOPE: pioglitazone offers the right cluster of effects to confer benefit in type 2 diabetes.
    Cardiovasc J Afr; 2008; 19(3):159-62. PubMed ID: 18568180
    [No Abstract]   [Full Text] [Related]  

  • 16. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
    Nitta Y; Tahara N; Tahara A; Honda A; Kodama N; Mizoguchi M; Kaida H; Ishibashi M; Hayabuchi N; Ikeda H; Yamagishi S; Imaizumi T
    JACC Cardiovasc Imaging; 2013 Nov; 6(11):1172-82. PubMed ID: 24229770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
    Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
    Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: randomized controlled trial (PioRAGE).
    Koyama H; Tanaka S; Monden M; Shoji T; Morioka T; Fukumoto S; Mori K; Emoto M; Shoji T; Fukui M; Fujii H; Nishizawa Y; Inaba M
    Atherosclerosis; 2014 Jun; 234(2):329-34. PubMed ID: 24727234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study.
    Langenfeld MR; Forst T; Hohberg C; Kann P; Lübben G; Konrad T; Füllert SD; Sachara C; Pfützner A
    Circulation; 2005 May; 111(19):2525-31. PubMed ID: 15883215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone + glimepiride: a combination product to avoid.
    Prescrire Int; 2007 Aug; 16(90):145. PubMed ID: 17724836
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.